目的 探討鼠神經因子聯合小牛血清對小兒腦性癱瘓的臨床療效。方法 選取廣元市婦幼保健院2015年1月-2017年6月收治的腦性癱瘓患兒60例，按治療方法分為對照組、觀察組，每組30例。對照組使用20 μg鼠神經生長因子注射液加2 mL滅菌注射用水溶解，肌肉注射，隔日1次，10 d為1療程，間隔10 d，共3個療程。觀察組在對照組的基礎上聯合使用20 mL小牛血清去蛋白注射液加200~300 mL 5%葡萄糖，靜脈滴注，每天1次，20 d為1療程，間隔10 d，共2個療程。比較兩組患兒治療前后發(fā)育商（DQ）評分的變化及臨床療效。結果 兩組患兒治療前的DQ評分無顯著性差異；治療后，兩組患兒的DQ評分均顯著提高，同組治療前后比較差異有統計學意義（P<0.05）；且觀察組的DQ評分顯著高于對照組，差異有統計學意義（P<0.05）。觀察組臨床療效的總有效率（86.67%）顯著高于對照組（73.33%），差異有統計學意義（P<0.05）。結論 鼠神經因子聯合小牛血清對小兒腦性癱瘓的療效較好，能提高患兒發(fā)育商評分，值得臨床應用和推廣。

Objective To explore the clinical efficacy of mouse nerve growth factor combined with calf serum in the treatment of pediatric cerebral palsy. Methods Selected 60 patients with cerebral palsy in our hospital from January 2015 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 30 cases. The control group was treated with mouse nerve growth factor. The observation group was treated with calf serum on basis of control group. The clinical efficacy and development quotient scores were compared between the two groups. Results There was no significant difference between the two groups of development quotient scores before the treatment. The DQ scores of the two groups both improved after treatment (P<0.05). The DQ score in observation group was higher than that in control group after treatment (P<0.05). The effective rate of clinical efficacy in observation group (86.67%) was higher than that in control group (73.33%) (P<0.05). Conclusions The clinical efficacy of mouse nerve growth factor combined with calf serum in treatment of pediatric cerebral palsy is fine, safe and reliable, worthy of clinical application and promotion.